Budget Impact Analysis of Biosimilar Infliximab (CT-P13) for the Treatment of Rheumatoid Arthritis in Six Central and Eastern European Countries

European Journal of Health Economics - Germany
doi 10.1007/s10198-014-0595-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Crohn's Disease in Six Central Eastern European Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

PMD13 Assessing the Budget Impact of Using ScanBag® in CT in Six European Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Pcn69 - Budget Impact of Substituting Biosimilar Trastuzumab (Ct-P6) in Treating Gastric Cancer and Breast Cancer in 28 European Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Editorial: CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Alpha Agent (Infliximab), in Inflammatory Bowel Diseases

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

AB0389 the Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses

2017English

Pms21 - Budget Impact Model of Inclusion of Tofacitinib for the Treatment of Rheumatoid Arthritis in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Clinical and Radiological Efficacy of Infliximab in the Treatment of Rheumatoid Arthritis

2018English

THU0218 the Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results From the Turkbio Registry

2018English

Central and Eastern European Countries (Information)

The Journal of Political Theory, Political Philosophy and Sociology of Politics Politeia
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy